CXCR2 and breast carcinoma: For example, CXCL1 could accelerate the immune escape of breast cancer (Li et al., 2021) and non‐small cell lung cancer (Lv et al., 2014) by recruiting CXCR2+ Tregs to establish immunosuppressive TME.